Publications by authors named "Marlies Blom"
Objective: To compare the effectiveness of a third tumor necrosis factor-α (TNF-α)-blocking agent with rituximab after failure of 2 TNF-blocking agents in patients with rheumatoid arthritis (RA) in daily clinical practice.
Methods: Patients receiving a third TNF-blocking agent or rituximab after failure of 2 TNF-blocking agents were selected from a Dutch biologic registry. The primary outcome was the results from the Disease Activity Score of 28 joints (DAS28) over the first 12 months after start of the third biologic using mixed-model analyses.
Rituximab treatment in patients with refractory inflammatory myopathies.
Rheumatology (Oxford)
December 2011
To assess the efficacy of rituximab on disease activity and muscle strength in patients with inflammatory myopathies refractory to conventional therapy. METHODS; Thirteen patients were treated with rituximab 1000 mg i.v.
View Article and Find Full Text PDFApproximately one-third of rheumatoid arthritis (RA) patients are seronegative for the 2 serological RA markers, rheumatoid factor (RF) and antibodies against cyclic citrullinated peptides (ACCP). Moreover, the sensitivities of both markers are lower in the diagnostically important early disease phase. The aim of this study was to identify additional autoantibody markers for early RA and for RF-negative, ACCP-negative (seronegative) RA.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate how effective the influenza vaccine is for rheumatoid arthritis patients treated with rituximab, along with its safety and the impact of prior vaccinations.
- In the trial, 23 RA patients receiving rituximab were compared to 20 on methotrexate and 29 healthy controls, with antibody levels measured 28 days post-vaccination.
- Results showed that while the methotrexate group and healthy controls had significant antibody increases after vaccination, the rituximab group did not, although the later subgroup showed some response to specific virus strains.
Objective: To investigate whether the reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent influences the effect of a second TNF blocking agent.
Methods: Data were used from 2 Dutch registries including patients with rheumatoid arthritis (RA) treated with TNF blocking agents. Patients were divided into 3 groups based on reason for discontinuation of the first: nonresponse, loss of response, or adverse events.
Objective: To study the outcome and complications of surgical treatment for vulvar vestibulitis syndrome and to identify patient characteristics that may have influenced the outcome.
Methods: Relevant patient characteristics were extracted retrospectively from the medical records of 155 women aged 40 years or younger who had received surgical treatment for vulvar vestibulitis syndrome. To assess outcome and complications, 126 of these 155 women (81%) participated in a telephone interview, conducted 1 to 4 years after surgery.